Improved Safety of Nucleic Acid Amplification Technology Combined With Serological Tests for Screening Blood Donors: A Systematic Review and Meta‐Analysis

No laboratory test performed to date provides an absolute guarantee for detecting infectious agents. Nucleic acid amplification techniques/tests (NAT) associated with serological tests can increase safety and provide greater diagnostic accuracy for patients. We investigated the added safety of NAT technology combined with serological tests for screening blood donors for Hepatitis C virus (HCV), human immunodeficiency virus (HIV) and hepatitis B virus (HBV). Data were obtained from a systematic search conducted up until march 30, 2024 in five electronic databases: PubMed, Web of Science, Scopus, Embase, and the Cochrane library. Twenty-nine studies, published between 1998 and 2023, were included in the review. Notably, HBV infection was predominant among donors with positive NAT results, with 425 cases, including 373 with positive serology and 52 with negative serology. Data from the diagnostic window period (WP) indicated the highest number of HBV infection cases, with 154 reported. Of the 29 included studies, 10 reported cases of occult HBV infection and diagnostic WP infection. Thirteen studies identified donors during the occult HBV infection period, and 17 identified WP cases. Meta-analyses of positive NAT results following negative serological screening for HBV, HCV, and HIV revealed a significantly pooled frequency (p < 0.001). Positive NAT results retrieved from donors with negative serological HBV and HCV showed a significantly combined frequency (p < 0.001), while for HIV occurs the opposite (p = 0.085). For HBV, HBC and HIV serological tests and NAT-positive results, the pooled frequency was significantly (p < 0.001). The findings demonstrate the positive relationship and safety of molecular technology in screening blood donors for HBV, HCV, and HIV using serological tests. Molecular testing remains a valuable tool for detecting and elucidating bloodborne infections.

Authors

Institutions

Publication Details

Journal
Reviews in Medical Virology
Published
2026-02-21
DOI
https://doi.org/10.1002/rmv.70117
Primary Topic
Hepatitis B Virus Studies
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Improved Safety of Nucleic Acid Amplification Technology Combined With Serological Tests for Screening Blood Donors: A Systematic Review and Meta‐Analysis

Maria Valdrinez Campana Lonardoni, Daniele Stéfanie Sara Lopes Lera‐Nonose, Maiara Vanusa Guedes Ribeiro, Áquila Carolina Fernandes Herculano Ramos‐Milaré et al.
Reviews in Medical Virology
Hepatitis B Virus Studies
article

Improved Safety of Nucleic Acid Amplification Technology Combined With Serological Tests for Screening Blood Donors: A Systematic Review and Meta‐Analysis

Maria Valdrinez Campana Lonardoni, Daniele Stéfanie Sara Lopes Lera‐Nonose, Maiara Vanusa Guedes Ribeiro, Áquila Carolina Fernandes Herculano Ramos‐Milaré, Aline Ávila Brustolin, Fernando Américo Jorge, Luciana Dias Ghiraldi, Jorge Juarez Vieira Teixeira, Dennis Armando Bertolini, Claudinei Mesquita da Silva, Heloise Skiavine Madeira, Raul Gomes Aguera, Marcos Elias da Silva Almeida, Débora de Castro Moreira, Leyde Daiane de Peder
article en

Abstract

No laboratory test performed to date provides an absolute guarantee for detecting infectious agents. Nucleic acid amplification techniques/tests (NAT) associated with serological tests can increase safety and provide greater diagnostic accuracy for patients. We investigated the added safety of NAT technology combined with serological tests for screening blood donors for Hepatitis C virus (HCV), human immunodeficiency virus (HIV) and hepatitis B virus (HBV). Data were obtained from a systematic search conducted up until march 30, 2024 in five electronic databases: PubMed, Web of Science, Scopus, Embase, and the Cochrane library. Twenty-nine studies, published between 1998 and 2023, were included in the review. Notably, HBV infection was predominant among donors with positive NAT results, with 425 cases, including 373 with positive serology and 52 with negative serology. Data from the diagnostic window period (WP) indicated the highest number of HBV infection cases, with 154 reported. Of the 29 included studies, 10 reported cases of occult HBV infection and diagnostic WP infection. Thirteen studies identified donors during the occult HBV infection period, and 17 identified WP cases. Meta-analyses of positive NAT results following negative serological screening for HBV, HCV, and HIV revealed a significantly pooled frequency (p < 0.001). Positive NAT results retrieved from donors with negative serological HBV and HCV showed a significantly combined frequency (p < 0.001), while for HIV occurs the opposite (p = 0.085). For HBV, HBC and HIV serological tests and NAT-positive results, the pooled frequency was significantly (p < 0.001). The findings demonstrate the positive relationship and safety of molecular technology in screening blood donors for HBV, HCV, and HIV using serological tests. Molecular testing remains a valuable tool for detecting and elucidating bloodborne infections.

Reviews in Medical VirologyVol. 36(2)
Universidade Estadual de Maringá (BR), Centro Universitário Fundação Assis Gurgacz (BR)
Good health and well-being
Openalex Percentile: Top 47%
Hepatitis B Virus Studies
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.